Actively Recruiting
Phase 3 Trial Comparing Xaluritamig Plus Abiraterone to Doctors Choice in Men with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Led by Amgen · Updated on 2026-07-24
750
Participants Needed
144
Research Sites
138 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating overall survival in men with chemotherapy-naive metastatic castration-resistant prostate cancer. This phase 3 study compares the combination of xaluritamig plus abiraterone with the investigators choice of treatment, which includes docetaxel, cabazitaxel, or abiraterone. The trial aims to assess which approach may affect survival outcomes in this patient population. Participants are assigned randomly to one of two groups. One group receives xaluritamig administered intravenously combined with oral abiraterone acetate daily. The other group receives the investigators choice of treatment oral abiraterone acetate daily, intravenous docetaxel every three weeks, or intravenous cabazitaxel every three weeks. Treatment continues with regular monitoring throughout the study. During the study, participants undergo various assessments including imaging scans and laboratory tests to track disease progression and response. Patient-reported outcomes on pain and quality of life are collected using standardized questionnaires. Researchers monitor adverse events and measure multiple outcomes such as progression-free survival, response rates, and prostate-specific antigen levels for up to approximately 51 months. The total study duration extends until August 2032.
CONDITIONS
Brief Title
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Research Team
A
Amgen Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
